The longer survival of patients whose medulloblastoma and glioma tumors at diagnosis contained higher PID1 mRNA7 suggested that these patients’ tumors may be more responsive to therapy and raised the possibility that PID1 may sensitize medulloblastomas and gliomas to chemotherapy. The gene discussed is PID1; the disease is medulloblastoma.